TScan Therapeutics (TCRX) Non-Current Assets (2020 - 2026)
TScan Therapeutics (TCRX) posted quarterly Non-Current Assets of $69.2 million for Q1 2026, down 11.11% year-over-year from $77.9 million in Q1 2025, and down 3.29% quarter-over-quarter from $71.6 million in Q4 2025.
TScan Therapeutics (TCRX) Non-Current Assets (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported Non-Current Assets for 7 consecutive years, with $69.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 11.11% year-over-year to $69.2 million; the TTM figure through Mar 2026 stood at $292.3 million (down 4.34% YoY), while the FY2025 annual figure was $71.6 million, down 8.69% from the prior year.
- Non-Current Assets eased to $69.2 million in Q1 2026 per TCRX's latest filing, from $71.6 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $78.4 million in Q4 2024 and bottomed at $22.5 million in Q1 2022.
- Historically, Non-Current Assets has averaged $65.8 million across 5 years, with a median of $74.1 million in 2025.
- Annual changes were most pronounced in 2022 — Non-Current Assets surged 233.87% — and 2026, when it retreated 11.11%.
- TScan Therapeutics' Non-Current Assets stood at $75.0 million in 2022, then climbed by 3.93% to $77.9 million in 2023, then climbed by 0.62% to $78.4 million in 2024, then decreased by 8.69% to $71.6 million in 2025, then slipped by 3.29% to $69.2 million in 2026.
- Business Quant data shows TCRX's Non-Current Assets at $69.2 million in Q1 2026, $71.6 million in Q4 2025, and $74.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | TScan Therapeutics | 100.62 Mn | 100.62 Mn | - | 67.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 67.05 Mn |
| Mar 31, 2026 | 69.23 Mn |
| Dec 31, 2025 | 71.58 Mn |
| Sep 30, 2025 | 74.06 Mn |
| Jun 30, 2025 | 77.43 Mn |
| Mar 31, 2025 | 77.87 Mn |
| Dec 31, 2024 | 78.40 Mn |
| Sep 30, 2024 | 73.94 Mn |
| Jun 30, 2024 | 75.34 Mn |
| Mar 31, 2024 | 76.11 Mn |
| Dec 31, 2023 | 77.91 Mn |
| Sep 30, 2023 | 73.81 Mn |
| Jun 30, 2023 | 74.71 Mn |
| Mar 31, 2023 | 72.67 Mn |
| Dec 31, 2022 | 74.96 Mn |
| Sep 30, 2022 | 24.28 Mn |
| Jun 30, 2022 | 23.06 Mn |
| Mar 31, 2022 | 22.46 Mn |
| Dec 31, 2021 | 22.45 Mn |
| Sep 30, 2021 | 17.89 Mn |